Utility of adjuvant systemic therapy in melanoma

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Eggermont, A M M ^a   Testori, A ^b   Marsden, J ^c   Hersey, P ^d   Quirt, I ^e   Petrella, T ^f   Gogas, H ^g   MacKie, R M ^h   Hauschild, A ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF KIEL   (Germany)

Author keywords

Adjuvant therapy; Interferon; Melanoma; Metastasis; Randomised trials

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; HUMAN; MELANOMA; REVIEW; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 70349577393     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp250     Document Type: Article

References (32)

1. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007; 34: 509-515.
2. Hersey P, Coates AS, McCarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20: 4181-4190.
3. Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20: 2058-2066.
4. Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20: 2067-2075.
5. Morton DL. Plenary presentation. In Annual Meeting of the Society of Surgical Oncology. Atlanta, GA, USA: 2006.
6. Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20: 4549-4554.
7. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-1044.
8. Eggermont AM, Suciu S, Ruka W et al. EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4 N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. 2008 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2008: 26 Abstr 9004.
9. Eggermont AM. The role of interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer 2001; 37: 2147-2153.
10. Gogas H, Dafni U, Bafaloukos D et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 Abstr 8505.
11. Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-1196.
12. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alpha-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.
13. Hauschild A, Volkenandt M, Tilgen W et al. Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of >1.5 mm tumor thickness: a randomized phase III DeCOG trial. 2008 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2008: 26 Abstr 9032.
14. Wheatley K, Ives N, Eggermont AM et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 Abstr 8526.
15. Grob JJ, Dreno B. de la Salmonière P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-1910.
16. Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425-1429.
17. Cameron DA, Cornbleet MC, Mackie RM et al. Adjuvant interferon alpha 2b in high risk melanoma-the Scottish study. Br J Cancer 2001; 84: 1146-1149.
18. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458.
19. Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53-61.
20. Cascinelli N, Belli F, MacKie RM et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358: 866-869.
21. Garbe C, Radny P, Linse R et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008; 19: 1195-1201.
22. Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with highdose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007; 25: 2078-2085.
23. Hauschild A, Weichenthal M, Balda BR et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21: 2883-2888.
24. Richtig E, Soyer HP, Posch M et al. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol 2005; 23: 8655-8663.
25. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-1825.
26. Wheatley K, Ives N, Hancock B et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-252.
27. Kirkwood JM, Manola J, Ibrahim J et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677.
28. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718.
29. Bouwhuis M, Suciu S, Kruit W et al. Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation (obs). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 Abstr 8507.
30. Stuckert JJ, Tarhini AA, Lee S et al. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 Abstr 8506.
31. Bouwhuis M, Suciu S, Testori A et al. Prognostic value of autoantibodies (auto-AB) in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b (PEG-IFN) vs observation. Eur J Cancer Suppl 2007; 5: 11 (Abstr 13BA).
32. Suciu S, Ghanem G, Kruit W et al. Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC randomized trial 18952 comparing IFNa versus observation. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 Abstr 8518.